# Incidental gallbladder cancer (found after cholecystectomy)

Source: https://onco.cc/cancers/incidental-gallbladder-cancer/  
OnCo record `incidental-gallbladder-cancer` (Cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Incidental gallbladder cancer is cancer the pathologist finds in a gallbladder removed for gallstones or inflammation, when nobody suspected it. It is the commonest way this cancer is found early enough to cure. Whether a second operation is needed depends on how deep the tumour went: none for the earliest layers, a radical operation at a specialist centre for T1b or deeper.

## Summary

Between one in 400 and one in 110 gallbladders removed for presumed benign disease contains a cancer (0.25 to 0.89 percent; Soreide 2019), and the share rises steeply with age (0.08 percent under 60 versus 0.67 percent over 60 in Denmark, where every specimen is examined; the surgeon had noted macroscopic changes in 27 of 28 cancers, Lerche-Jorgensen 2025). About half are pT2 and a third pT1. Patients whose cancer is confined to the mucosa (T1a or less) have five-year survival of up to 100 percent after the cholecystectomy alone; for T1b or deeper tumours re-resection is recommended, though its type, extent and timing remain debated (Soreide 2019; AHPBA consensus, Aloia 2015). Ten US academic centres found re-resection between 4 and 8 weeks after the first operation gave the longest survival (median 40.4 months, against 17.4 months under 4 weeks and 22.4 months over 8 weeks), the interval allowing new CT or MRI and PET-CT, which can show residual or distant disease and prevent a futile operation (Ethun 2017; Soreide 2019). Perforation of the gallbladder at the first operation raises the risk of dissemination, and the risk of peritoneal spread rises with each T category. Port-site metastases occurred in 18.6 percent of laparoscopic cases before 2000 and 10.3 percent since (Berger-Richardson 2017); routine excision of the port sites does not improve survival (Soreide 2019). Routine staging laparoscopy before re-resection is not needed for every stage. Adjuvant chemotherapy after re-resection is poorly documented and probably underused (Soreide 2019).

Getting patients to the right place is the weak link: in 27 Dutch secondary hospitals only 53.9 percent of 243 patients eligible for re-resection (pT1b to pT3, M0) were referred to a tertiary centre, and in nearly half of the non-referred the reason was not documented (van Dooren 2024). In the UK the specialist hepatobiliary multidisciplinary team is the route; two UK units have described their approach to suspected cancer, using intraoperative frozen section to decide on extending surgery at the first operation (Chan 2022, Liverpool; Banh 2024, London). The UK pathway page carries referral detail; this page covers what the finding means.

## Fields

- Kind: Cancer
- Last checked: 2026-09-24
- Also known as: Incidentally discovered gallbladder cancer; Unsuspected gallbladder cancer; Occult gallbladder cancer; IGBC
- Tags: gallbladder; biliary; subtype-page
- Group: gastrointestinal
- Burden: 0.25 to 0.89 percent of all cholecystectomy specimens in the series reviewed by Soreide (2019); 0.29 percent of 9,698 in a Danish department, 0.08 percent under 60 and 0.67 percent over 60 (Lerche-Jorgensen 2025). Roa and colleagues say most gallbladder cancers are found this way.
- Subtypes: Incidental gallbladder cancer, Tis or T1a (cholecystectomy alone is curative); Incidental gallbladder cancer, T1b or deeper (re-resection recommended); Incidental gallbladder cancer with a positive cystic duct margin (bile duct resection added); Incidental gallbladder cancer with gallbladder perforation or bile spillage at the first operation (higher risk of peritoneal and port-site spread)
- Biomarkers: T category on the specimen (the single decision-maker); Cystic duct margin status; Whether the gallbladder was perforated or bile spilled at the first operation; Interval since cholecystectomy (4 to 8 weeks target); Residual or distant disease on interval CT, MRI and PET-CT

## Standard of care

- Tis or T1a with a clear cystic duct margin: No further surgery; the simple cholecystectomy is treatment enough. ([Simple cholecystectomy](https://onco.cc/terms/simple-cholecystectomy/), [Cystic duct margin](https://onco.cc/terms/cystic-duct-margin/))
- T1b, T2 or T3, no metastases: Referral to a hepatobiliary centre; interval CT or MRI and PET-CT; radical cholecystectomy (liver bed plus portal lymphadenectomy) at 4 to 8 weeks, with bile duct resection only for a positive cystic duct margin; port sites not routinely excised; adjuvant capecitabine after. ([Radical (extended) cholecystectomy](https://onco.cc/terms/radical-cholecystectomy/), [Segment IVb and V liver resection (versus wedge resection)](https://onco.cc/terms/segment-ivb-v-resection/), [Lymphadenectomy (lymph node dissection)](https://onco.cc/terms/lymphadenectomy/), [Cystic duct margin](https://onco.cc/terms/cystic-duct-margin/), [Port-site metastasis](https://onco.cc/terms/port-site-metastasis/), [PET/CT](https://onco.cc/technologies/pet-ct/), [Capecitabine](https://onco.cc/drugs/capecitabine/), [BILCAP](https://onco.cc/trials/bilcap/))
- Residual disease found on interval imaging or at re-operation: Systemic treatment as for advanced gallbladder cancer. ([Gemcitabine + cisplatin](https://onco.cc/drugs/gemcitabine-cisplatin/), [Durvalumab](https://onco.cc/drugs/durvalumab/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/))

## State of the art

- The 4 to 8 week window is the practical lesson of the last decade: long enough for imaging and referral, not so long that the disease progresses.
- PET-CT before re-resection spares some patients an operation that would not have helped.
- Port-site excision has been dropped from routine practice.

## Open problems

- Whether T1b tumours need re-resection: two 2024 to 2026 analyses disagree on disease-specific benefit.
- How many UK patients with an incidental cancer reach a hepatobiliary centre is not published.
- Whether every gallbladder needs histological examination, or a selective policy based on age and the surgeon's inspection would be safe.

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Cholecystectomy
- Soreide, Br J Surg 2019: systematic review of incidental gallbladder cancer after cholecystectomy: https://doi.org/10.1002/bjs.11035
- Ethun, JAMA Surg 2017: timing of re-resection for incidental gallbladder cancer: https://doi.org/10.1001/jamasurg.2016.3642
- Berger-Richardson, Surgery 2017: trends in port-site metastasis after laparoscopic resection of incidental gallbladder cancer: https://doi.org/10.1016/j.surg.2016.08.007
- Lerche-Jorgensen, Dan Med J 2025: incidental gallbladder cancer in 9,698 cholecystectomies: https://doi.org/10.61409/a11240787
- van Dooren, BJS Open 2024: referral of incidental gallbladder cancer from 27 Dutch secondary centres: https://doi.org/10.1093/bjsopen/zrae013
- AHPBA expert consensus statement on gallbladder cancer (Aloia, HPB 2015): https://doi.org/10.1111/hpb.12444
- Chan, J Surg Oncol 2022: intraoperative frozen section for suspected gallbladder cancer (Liverpool): https://doi.org/10.1002/jso.26726
- Banh, Int J Surg 2024: single-stage management of suspected gallbladder cancer with frozen section (London): https://doi.org/10.1097/js9.0000000000001456
- Cho, Ann Hepatobiliary Pancreat Surg 2026: extended versus simple cholecystectomy for T1b, meta-analysis: https://doi.org/10.14701/ahbps.26-091
- Rhodin, HPB 2024: simple versus radical cholecystectomy for T1b in the National Cancer Database: https://doi.org/10.1016/j.hpb.2024.01.012
- Roa, Nature Reviews Disease Primers 2022: gallbladder cancer: https://doi.org/10.1038/s41572-022-00398-y
- NHS: tests and next steps for gallbladder cancer: https://www.nhs.uk/conditions/gallbladder-cancer/tests-and-next-steps/

## Connected records

- cancers: [Carcinoma in situ and dysplasia of the gallbladder](https://onco.cc/cancers/gallbladder-carcinoma-in-situ-and-dysplasia/), [Cystic duct carcinoma](https://onco.cc/cancers/cystic-duct-carcinoma/), [Gallbladder adenocarcinoma](https://onco.cc/cancers/gallbladder-adenocarcinoma/), [Gallbladder cancer](https://onco.cc/cancers/gallbladder/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/), [Durvalumab](https://onco.cc/drugs/durvalumab/), [Gemcitabine + cisplatin](https://onco.cc/drugs/gemcitabine-cisplatin/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- terms: [Cystic duct margin](https://onco.cc/terms/cystic-duct-margin/), [Lymphadenectomy (lymph node dissection)](https://onco.cc/terms/lymphadenectomy/), [Port-site metastasis](https://onco.cc/terms/port-site-metastasis/), [Radical (extended) cholecystectomy](https://onco.cc/terms/radical-cholecystectomy/), [Segment IVb and V liver resection (versus wedge resection)](https://onco.cc/terms/segment-ivb-v-resection/), [Simple cholecystectomy](https://onco.cc/terms/simple-cholecystectomy/)
- trials: [BILCAP](https://onco.cc/trials/bilcap/), [NEOGB](https://onco.cc/trials/neogb/), [OPT-IN (EA2197)](https://onco.cc/trials/opt-in/), [POLCAGB](https://onco.cc/trials/polcagb/)
- technologies: [PET/CT](https://onco.cc/technologies/pet-ct/), [Surgery for gallbladder cancer: simple versus radical cholecystectomy, re-resection and lymphadenectomy](https://onco.cc/technologies/gallbladder-cancer-surgery/)
- key papers: [Association of Optimal Time Interval to Re-resection for Incidental Gallbladder Cancer With Overall Survival: A Multi-Institution Analysis From the US Extrahepatic Biliary Malignancy Consortium](https://onco.cc/key-papers/paper-ethun-re-resection-timing-incidental-gallbladder-cancer-jama-surg-2017/), [Carcinoma of the gallbladder: staging, treatment, and prognosis](https://onco.cc/key-papers/paper-nevin-gallbladder-carcinoma-staging-cancer-1976/), [Gallbladder cancer](https://onco.cc/key-papers/paper-roa-gallbladder-cancer-primer-nat-rev-dis-primers-2022/), [Incidence of finding residual disease for incidental gallbladder carcinoma: implications for re-resection](https://onco.cc/key-papers/paper-pawlik-incidental-gallbladder-cancer-residual-disease-jgs-2007/), [Incidental Carcinoma after Cholecystectomy for Benign Disease of the Gallbladder: A Meta-Analysis](https://onco.cc/key-papers/paper-pyo-incidental-gallbladder-cancer-meta-analysis-jcm-2020/), [Management of incidental gallbladder cancer in the nationwide CAPBIL study](https://onco.cc/key-papers/paper-mcclements-capbil-incidental-gallbladder-cancer-bjs-2026/), [Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally detected gallbladder carcinoma after simple cholecystectomy or in front of radical resection of BTC (ICC/ECC) - a phase III study of the German registry of incidental gallbladder carcinoma platform (GR)- the AIO/ CALGP/ ACO- GAIN-trial](https://onco.cc/key-papers/paper-gain-trial-protocol-bmc-cancer-2020/), [Neoadjuvant treatment for incidental gallbladder cancer: A systematic review](https://onco.cc/key-papers/paper-varshney-neoadjuvant-incidental-gallbladder-cancer-systematic-review-ahbps-2025/), [Optimal surgical treatment in patients with T1b gallbladder cancer: An international multicenter study](https://onco.cc/key-papers/paper-kim-t1b-gallbladder-cancer-international-jhbps-2018/), [Re-resection in Incidental Gallbladder Cancer: Survival and the Incidence of Residual Disease](https://onco.cc/key-papers/paper-de-savornin-lohman-re-resection-incidental-gallbladder-cancer-aso-2020/), [Systematic review of management of incidental gallbladder cancer after cholecystectomy](https://onco.cc/key-papers/paper-soreide-incidental-gallbladder-cancer-review-bjs-2019/), [Timing of revision surgery for incidental gallbladder cancer: a systematic review and individual patient data meta-analysis](https://onco.cc/key-papers/paper-selvakumar-revision-surgery-timing-ipd-meta-analysis-hpb-2026/)
- roadmaps: [Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials](https://onco.cc/roadmaps/gallbladder-cancer-roadmap/)
- ideas: [A national incidental gallbladder cancer pathway: histology for every gallbladder, referral within two weeks, re-resection by eight](https://onco.cc/ideas/idea-gbc-national-incidental-cancer-pathway/), [Chemotherapy before the second operation for high-risk incidental gallbladder cancer](https://onco.cc/ideas/idea-gbc-neoadjuvant-for-high-risk-incidental-cancer/), [Test whether T1b gallbladder cancer needs the second operation at all](https://onco.cc/ideas/idea-gbc-t1b-simple-cholecystectomy-prospective-study/)

---
JSON: https://onco.cc/api/v1/entities/incidental-gallbladder-cancer.json